Abstract:Today, persistent and uncontrolled inflammation is appreciated to play a pivotal role in many diseases, such as cardiovascular diseases, neurodegenerative diseases, metabolic syndrome and many other diseases of public health concern (e.g. Coronavirus Disease 2019 (COVID-19) and periodontal disease). The ideal response to initial challenge in humans is a self-limited inflammatory response leading to complete resolution. The resolution phase is now widely recognized as a biosynthetically active process, governed by a superfamily of endogenous chemical mediators that stimulate resolution of inflammatory responses, namely specialized proresolving mediators (SPMs). Because resolution is the natural ideal response, the SPMs have gained attention. SPMs are mediators that include ω-6 arachidonic acid-derived lipoxins, ω-3 eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)-derived resolvins, protectins and maresins, cysteinyl-SPMs, as well as n-3 docosapentaenoic acid (DPA)-derived SPMs. These novel immunoresolvents, their biosynthetic pathways and receptors have proven to promote resolution of inflammation, clearance of microbes, reduce pain and promote tissue regeneration via specific cellular and molecular mechanisms. As of 17 August, 2020, PubMed.gov reported >1170 publications for resolvins, confirming their potent protective actions from many laboratories worldwide. Since this field is rapidly expanding, we provide a short update of advances within 2-3 years from human and preclinical animal studies, together with the structural-functional elucidation of SPMs and identification of novel SPM receptors. These new discoveries indicate that SPMs, their pathways and receptors could provide a basis for new approaches for treating inflammation-associated diseases and for stimulating tissue regeneration via resolution pharmacology and precision nutrition.

Specialized pro-resolving mediator network: an update on production and actions

Specialized pro-resolving mediators - Key players in resolution

New Advances in Targeting the Resolution of Inflammation: Implications for Specialized Pro-Resolving Mediator GPCR Drug Discovery

Design of nanoformulation of specialized pro-resolving mediators to facilitate inflammation resolution and disease treatment

Endogenous pro-resolving and anti-inflammatory lipid mediators: a new pharmacologic genus

Specialized Proresolving Mediators for Therapeutic Interventions Targeting Metabolic and Inflammatory Disorders

Pro-resolving lipid mediators are leads for resolution physiology

Low-dose pro-resolving mediators temporally reset the resolution response to microbial inflammation

Resolvins, Specialized Proresolving Lipid Mediators, and Their Potential Roles in Metabolic Diseases

Advance in Pro-Resolution Lipid Mediators and Mechanisms of Inflammation Resolution

Inflammation resolution and specialized pro-resolving lipid mediators in CNS diseases

Specialized Pro-Resolving Mediators as Resolution Pharmacology for the Control of Pain and Itch

Resolution medicine in cancer, infection, pain and inflammation: are we on track to address the next Pandemic?

Is Lipid Metabolism of Value in Cancer Research and Treatment? Part II: Role of Specialized Pro-Resolving Mediators in Inflammation, Infections, and Cancer

Specialized pro-resolving lipid mediators: A new class of non-immunosuppressive and non-opioid analgesic drugs

Specialized pro-resolving mediators in vascular inflammation and atherosclerotic cardiovascular disease

Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators

Resolvins: Anti-Inflammatory and Proresolving Mediators Derived from Omega-3 Polyunsaturated Fatty Acids

Roles of specialized pro-resolving mediators and omega-3 polyunsaturated fatty acids in periodontal inflammation and impact on oral microbiota

Resolvins and protectins in the termination program of acute inflammation

Specialized Pro-resolving Mediator Improves Vascular Relaxation via Formyl Peptide Receptor-2